Subjects: Opioid-Related Disorders -- drug therapy - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Opioid-Related Disorders -- drug therapy ✖

1. Buprenorphine: an overview for clinicians

Author(s):: Steiger, Scott, author
DeFries, Triveni, author
Publication:: [Oakland, California] : California Health Care Foundation, August 2019
Subject(s):: Buprenorphine -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Ambulatory Care
Buprenorphine -- administration & dosage
Buprenorphine -- adverse effects
Drug and Narcotic Control
Emergency Service, Hospital
Health Services Accessibility
Mental Health Services
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Pain -- drug therapy
Prescription Drug Diversion
Prisons
State Government
Telemedicine
Humans
California
United States

2. Catalyzing Medicaid policy research with T-MSIS Analytic Files (TAF): learnings from year 1 of the Medicaid Data Learning Network (MDLN)

Author(s):: Gordon, Sarah, (Of Boston University), author
Johnson, Annaliese, author
Kennedy, Susan, (Of AcademyHealth), author
McConnel, John, (Of Oregon Health & Science University), author
Schpero, William, author
Publication:: Washington, DC : AcademyHealth, May 15, 2023
Subject(s):: Datasets as Topic
Health Policy
Health Services Research
Medicaid -- statistics & numerical data
Ethnicity
Fee-for-Service Plans
Health Expenditures
Information Storage and Retrieval
Managed Care Programs
Maternal Health
Opioid-Related Disorders -- drug therapy
Racial Groups
Reproductive Health
Utilization Review
United States

3. The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2023
Subject(s):: Government Regulation
Medicare
Opiate Overdose -- prevention & control
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States

4. Dear Doctor, I wish to call your attention to our remedy, Manine, for the treatment and cure of that diseased condition of the nervous system caused by the use of morphine, laudanum, heroin or opium in any of its forms

Author(s):: Manine Medicine Company, author.
Publication:: St. Louis, Missouri : Manine Medicine Company, [1913?]
Subject(s):: Opioid-Related Disorders -- drug therapy
Nonprescription Drugs

5. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 2, 2022
Subject(s):: Buprenorphine -- therapeutic use
Drug Prescriptions -- statistics & numerical data
Drug Utilization -- statistics & numerical data
Drug Utilization -- trends
Opioid-Related Disorders -- drug therapy
Practice Guidelines as Topic
Scope of Practice
United States
United States. Department of Health and Human Services.

6. Expanding access to naloxone: a review of distribution strategies

Author(s):: Weiner, Janet, author
Murphy, Sean , author
Behrends, Czarina, author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2019
Subject(s):: Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Services Accessibility
Naloxone -- supply & distribution
Naloxone -- therapeutic use
Opioid-Related Disorders -- drug therapy
Community Health Services
Emergency Responders
Nonprescription Drugs
Opioid-Related Disorders -- epidemiology
Pharmacies
Humans
United States

7. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):: Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

8. Geographic disparities affect access to buprenorphine services for opioid use disorder

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, January 2020
Subject(s):: Buprenorphine -- supply & distribution
Health Services Accessibility
Medically Underserved Area
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
United States. Department of Health and Human Services
United States. Substance Abuse and Mental Health Services Administration

9. How community health centers are addressing the opioid epidemic: case study

Author(s):: Hayes, Robert M., author
Squitieri, Joseph, author
Publication:: New York, NY : Milbank Memorial Fund, April 2019
Subject(s):: Child of Impaired Parents
Community Health Centers
Community Health Services
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Adolescent
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Child
Community Mental Health Services
Drug Overdose -- prevention & control
Humans
United States

10. Increasing access to medications for opioid use disorder: policy strategies during and after COVID-19 pandemic

Author(s):: Au-Yeung, Caroline M., author
Blewett, Lynn A., author
Winkelman, Tyler N.A., author
Publication:: New York, NY : Milbank Memorial Fund, October 2021
Subject(s):: Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
COVID-19
Health Policy
Methadone -- therapeutic use
Naltrexone -- therapeutic use
United States